dydrogesterone 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
steroids, progestogens 975 152-62-5

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • dydrogesterone
  • hydrogesterone
  • isopregnenone
A synthetic progestational hormone with no androgenic or estrogenic properties. Unlike many other progestational compounds, dydrogesterone produces no increase in temperature and does not inhibit OVULATION.
  • Molecular weight: 312.45
  • Formula: C21H28O2
  • CLOGP: 3.54
  • LIPINSKI: 0
  • HAC: 2
  • HDO: 0
  • TPSA: 34.14
  • ALOGS: -4.81
  • ROTB: 1
  • Status: OFM
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
10 mg O

ADMET properties:

PropertyValueReference
BA (Bioavailability) 28 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
S (Water solubility) 0.00 mg/mL Bocci G, Oprea TI, Benet LZ
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Bocci G, Oprea TI, Benet LZ

Approvals:

DateAgencyCompanyOrphan
None FDA SOLVAY
Dec. 1, 1965 PMDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Ovarian hyperstimulation syndrome 115.57 56.02 21 488 3993 63484520
Maternal exposure during pregnancy 78.62 56.02 37 472 220025 63268488
Placenta accreta 76.26 56.02 10 499 216 63488297

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Ovarian hyperstimulation syndrome 118.84 60.89 20 422 3551 79740395
Maternal exposure during pregnancy 97.41 60.89 34 408 136504 79607442
Placenta accreta 80.56 60.89 10 432 203 79743743

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC G03DB01 GENITO URINARY SYSTEM AND SEX HORMONES
SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM
PROGESTOGENS
Pregnadien derivatives
ATC G03FA14 GENITO URINARY SYSTEM AND SEX HORMONES
SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM
PROGESTOGENS AND ESTROGENS IN COMBINATION
Progestogens and estrogens, fixed combinations
ATC G03FB08 GENITO URINARY SYSTEM AND SEX HORMONES
SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM
PROGESTOGENS AND ESTROGENS IN COMBINATION
Progestogens and estrogens, sequential preparations
MeSH PA D006728 Hormones
MeSH PA D011372 Progestins
CHEBI has role CHEBI:59826 progestins

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Luteal phase support indication 6738008
Prevention of premature ovulation during controlled ovarian stimulation indication 732970000




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Progesterone receptor Nuclear hormone receptor AGONIST Ki 6.90 IUPHAR CHEMBL
Nuclear receptor subfamily 2 group E member 1 Nuclear hormone receptor Kd 4.56 SCIENTIFIC LITERATURE

External reference:

IDSource
N0000167428 NUI
D01217 KEGG_DRUG
C0013340 UMLSCUI
CHEBI:31527 CHEBI
CHEMBL1200853 ChEMBL_ID
DB00378 DRUGBANK_ID
D004394 MESH_DESCRIPTOR_UI
9051 PUBCHEM_CID
2878 IUPHAR_LIGAND_ID
970 INN_ID
90I02KLE8K UNII
3706 RXNORM
001296 NDDF
126093005 SNOMEDCT_US
43753001 SNOMEDCT_US

Pharmaceutical products:

None